Premature Mortality Post Fracture:A NSW Linked Data Study
Funder
National Health and Medical Research Council
Funding Amount
$391,012.00
Summary
Osteoporotic fractures are associated with increased morbidity and mortality. Anti-osteoporosis medications reduce re-fracture and possibly morality, yet osteoporosis is poorly treated. This study will link information from >260,000 people (45&Up study) with hospital admissions, medications and deaths to create the largest, detailed dataset of its kind. We will be able to determine cause of any fracture-associated mortality and the effect of medication to improve osteoporosis management.
This study will follow up a birth cohort for 25 years with the aim of looking at critical periods for bone development including the role of in utero exposures, early infancy, age 8 and age 16.
Fracture Associated Premature Mortality; An International Consortium
Funder
National Health and Medical Research Council
Funding Amount
$579,807.00
Summary
Following an osteoporotic fracture there is an increased premature mortality compared with someone who has not fractured. There is also evidence that anti-osteoporosis medication reduces this premature mortality. This study will determine the size of the fracture-mortality relationship and the effect of treatment on this mortality for different fracture types and in different populations by integrating data from multiple international epidemiology studies of osteoporosis.
Prediction Of Adverse Outcomes Following A Fragility Fracture
Funder
National Health and Medical Research Council
Funding Amount
$148,426.00
Summary
Individuals with an existing fracture are at increased risk of adverse outcomes such as re-fracture and premature mortality, but it is not clear why. We propose to evaluate risk factors, and prognostic models, for predicting the risk of adverse outcomes. We also propose to develop a quantitative risk-benefit framework for evaluating the clinical utility of such prognostic models and help ensure that therapies appropriately address real-life experience of osteoporotic patients.
Prevention And Treatment Of Bone Infection With CSA-90
Funder
National Health and Medical Research Council
Funding Amount
$350,983.00
Summary
Bone infections are a major challenge to treat, especially with the rise of drug resistant “superbugs”. We have access to a new agent, CSA-90, that has dual properties of being anti-microbial (antibiotic) and helps encourage bone growth. This project aims to expand upon our prior research and test CSA-90 for the treatment of chronic bone infections. We will also look at applying this technology to joint replacements and this drug may be particularly useful for coating orthopaedic implants.
Osteal Macrophages As Therapeutic Targets For Fracture Repair
Funder
National Health and Medical Research Council
Funding Amount
$618,015.00
Summary
Fragility fracture associated with osteoporosis is a substantial health problem costing $1.62 billion to treat in 2012 in Australia. There is no approved therapy to improve and accelerate fracture healing to help reduce this increasing health burden. This research will advance understanding of fracture repair in healthy and osteoporotic bone and progress development of a fracture therapy to improve bone repair by promoting specialised immune cells.
International Orthopaedic Multicenter Study In Fracture Care (INORMUS)
Funder
National Health and Medical Research Council
Funding Amount
$1,462,437.00
Summary
INORMUS is a global multi-centre prospective cohort study in 40,000 patients with musculoskeletal trauma (e.g. fractures or dislocations) to determine the incidence of major trauma complications (i.e. mortality, re-operations, and infections) and to examine a number of factors that may predict early complications. This study will allow us to address fundamental questions for the millions of adults worldwide who experience trauma annually and will have immense public health implications.
Fractures And Bisphosphonates: Reviving Osteoporosis Treatment Uptake By Identifying The Genetic, Material, And Microstructural Risk Factors Of Atypical Femur Fractures.
Funder
National Health and Medical Research Council
Funding Amount
$1,053,094.00
Summary
Atypical femoral fractures (AFF) are uncommon, but catastrophic, complications of antiresorptive osteoporosis treatments including bisphosphonates. We will identify patients at risk of AFF by determining changes in their bone structure and quality, and identifying genes that increase the risk of these fractures. In this way, cheap and effective antiresorptive treatments can be targeted to patients at the lowest risk of AFF and alternative treatments to those at highest risk.
The ASPREE-fracture Sub-study: Does Daily Low-dose Aspirin Reduce Fracture Risk In Healthy Older Adults?
Funder
National Health and Medical Research Council
Funding Amount
$1,351,150.00
Summary
Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. This is despite decades of clinical research, best practice guidelines and advances in therapies that aim to reduce fracture risk. The World Health Organization has identified fracture prevention as a public health priority. This study will determine whether a widely available, simple and inexpensive health intervention—aspirin—can reduce the incidence of fracture and associated disability ....Disability, mortality and healthcare burden from fractures in older people is a growing problem worldwide. This is despite decades of clinical research, best practice guidelines and advances in therapies that aim to reduce fracture risk. The World Health Organization has identified fracture prevention as a public health priority. This study will determine whether a widely available, simple and inexpensive health intervention—aspirin—can reduce the incidence of fracture and associated disability amongst older Australians.Read moreRead less
Whole Body Vibration For Osteoporosis: Shaking Up Our Treatment Options
Funder
National Health and Medical Research Council
Funding Amount
$961,017.00
Summary
Our aim is to examine the ability of vibration alone and in combination with osteoporosis drugs to reduce hip fracture in postmenopausal women. In Australia, 1 in 2 women >60yrs, will sustain an osteoporotic fracture. Only drugs notably decrease fracture; however none are entirely effective and some patients don’t respond. Whole body vibration has emerged as a potentially effective therapy. A combination of vibration and drugs may enhance the effects of both and revolutionise treatment.